Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06095388 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase I/II Study of JR-441 in Patients With Mucopolysaccharidosis Type IIIA

StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv5
  2. Trial status: Recruiting to Active, Not Recruitingv4 Show 4 more changesShow less
    • Enrollment target: estimated 12 to confirmed 15
    • Interventions: JR-441 (Drug), JR-441 (Drug) to JR-441 (Drug), JR-441 (Drug), JR-441 (Drug)
    • Site details revised
    • Study arms: 2 to 3
  3. 2 versions Re-verified since May 9, 2025, no change to tracked fieldsv2-v3
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Phase I/ II, open-label, randomized, 2-arm study, designed to evaluate the safety and explore efficacy of the study drug in development for the treatment of MPS IIIA patients.
Trial Details
NCT Number NCT06095388
Lead Sponsor JCR Pharmaceuticals Co., Ltd.
Conditions
(from sponsor)		 Mucopolysaccharidosis III-A
Related terms Mucopolysaccharidosis III
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov